A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Taselisib (Primary)
  • Indications Breast cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 12 Mar 2016 Results (n = 54) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 31 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2014 Planned number of patients changed from 36 to 56 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top